China · Delayed Price · Currency is CNY Sansure Biotech Statistics
Total Valuation
Sansure Biotech has a market cap or net worth of CNY 9.50 billion. The enterprise value is 7.28 billion.
| Market Cap | 9.50B |
| Enterprise Value | 7.28B |
Important Dates
The next confirmed earnings date is Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Jun 22, 2026 |
Share Statistics
Sansure Biotech has 568.11 million shares outstanding. The number of shares has decreased by -0.67% in one year.
| Current Share Class | 568.11M |
| Shares Outstanding | 568.11M |
| Shares Change (YoY) | -0.67% |
| Shares Change (QoQ) | -14.53% |
| Owned by Insiders (%) | 39.48% |
| Owned by Institutions (%) | 9.46% |
| Float | 291.80M |
Valuation Ratios
The trailing PE ratio is 72.60 and the forward PE ratio is 38.29.
| PE Ratio | 72.60 |
| Forward PE | 38.29 |
| PS Ratio | 5.91 |
| PB Ratio | 1.34 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 30.53 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 54.26 |
| EV / Sales | 4.53 |
| EV / EBITDA | 27.06 |
| EV / EBIT | 198.82 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.67 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 5.67 |
| Debt / FCF | -26.05 |
| Interest Coverage | 1.43 |
Financial Efficiency
Return on equity (ROE) is 1.28% and return on invested capital (ROIC) is 0.73%.
| Return on Equity (ROE) | 1.28% |
| Return on Assets (ROA) | 0.24% |
| Return on Invested Capital (ROIC) | 0.73% |
| Return on Capital Employed (ROCE) | 0.43% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | 778,697 |
| Profits Per Employee | 65,036 |
| Employee Count | 2,064 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.02 |
Taxes
In the past 12 months, Sansure Biotech has paid 7.87 million in taxes.
| Income Tax | 7.87M |
| Effective Tax Rate | 7.85% |
Stock Price Statistics
The stock price has decreased by -18.52% in the last 52 weeks. The beta is 0.43, so Sansure Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -18.52% |
| 50-Day Moving Average | 15.81 |
| 200-Day Moving Average | 17.33 |
| Relative Strength Index (RSI) | 58.65 |
| Average Volume (20 Days) | 4,533,708 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sansure Biotech had revenue of CNY 1.61 billion and earned 134.24 million in profits. Earnings per share was 0.23.
| Revenue | 1.61B |
| Gross Profit | 1.17B |
| Operating Income | 36.63M |
| Pretax Income | 100.37M |
| Net Income | 134.24M |
| EBITDA | 261.39M |
| EBIT | 36.63M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 3.82 billion in cash and 1.53 billion in debt, with a net cash position of 2.30 billion or 4.04 per share.
| Cash & Cash Equivalents | 3.82B |
| Total Debt | 1.53B |
| Net Cash | 2.30B |
| Net Cash Per Share | 4.04 |
| Equity (Book Value) | 7.07B |
| Book Value Per Share | 12.26 |
| Working Capital | 3.98B |
Cash Flow
In the last 12 months, operating cash flow was 311.15 million and capital expenditures -369.68 million, giving a free cash flow of -58.53 million.
| Operating Cash Flow | 311.15M |
| Capital Expenditures | -369.68M |
| Depreciation & Amortization | 224.76M |
| Net Borrowing | 552.45M |
| Free Cash Flow | -58.53M |
| FCF Per Share | -0.10 |
Margins
Gross margin is 72.64%, with operating and profit margins of 2.28% and 8.35%.
| Gross Margin | 72.64% |
| Operating Margin | 2.28% |
| Pretax Margin | 6.24% |
| Profit Margin | 8.35% |
| EBITDA Margin | 16.26% |
| EBIT Margin | 2.28% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.52, which amounts to a dividend yield of 3.13%.
| Dividend Per Share | 0.52 |
| Dividend Yield | 3.13% |
| Dividend Growth (YoY) | -0.38% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 245.06% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.67% |
| Shareholder Yield | 3.80% |
| Earnings Yield | 1.41% |
| FCF Yield | -0.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.48.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
Sansure Biotech has an Altman Z-Score of 4.03 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.03 |
| Piotroski F-Score | 5 |